Trial Profile

A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of SARS-CoV-2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 60 Years of Age

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II/III

Latest Information Update: 14 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SARS-CoV-2 rS+trivalent hemagglutinin nanoparticle influenza combination vaccine Novavax (Primary) ; Influenza virus vaccine
Indications COVID 2019 infections
Focus Adverse reactions; Registrational
Sponsors Novavax

11 Mar 2025 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: It was decided to not move forward with the study.
12 Dec 2024 Planned End Date changed from 17 May 2025 to 17 May 2026.
12 Dec 2024 Planned primary completion date changed from 16 Nov 2024 to 16 Nov 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com